Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Other Accumulated Expenses (2023 - 2025)

Immucell (ICCC) has disclosed Other Accumulated Expenses for 3 consecutive years, with $264832.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses fell 29.59% year-over-year to $264832.0, compared with a TTM value of $264832.0 through Sep 2025, down 29.59%, and an annual FY2024 reading of $234552.0, up 21.68% over the prior year.
  • Other Accumulated Expenses was $264832.0 for Q3 2025 at Immucell, up from $147790.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $376112.0 in Q3 2024 and bottomed at $131539.0 in Q1 2025.
  • Average Other Accumulated Expenses over 3 years is $224596.5, with a median of $213653.0 recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses increased 21.68% in 2024, then dropped 29.59% in 2025.
  • Year by year, Other Accumulated Expenses stood at $192754.0 in 2023, then rose by 21.68% to $234552.0 in 2024, then increased by 12.91% to $264832.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for ICCC at $264832.0 in Q3 2025, $147790.0 in Q2 2025, and $131539.0 in Q1 2025.